TAKEDA PHARMACEUTICAL CO LTD
For the period ended Oct 29, 2026. Filed Oct 29, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Oct 29, 2026 · Filed Oct 29, 2026
Use the contents to explore the available documents and sections.
Contents
Cover page
Show cover page
6-K 1 form6k-1_102926.htm 6-K
FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Commission File Number: 001-38757
For the month of October 2026
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668
Japan
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information furnished on this form:
EXHIBIT
| ExhibitNumber | |
|---|---|
| 1. | (English Translation) Earnings Report (Kessan Tanshin) for the Six-month Period Ended September 30, 2026 |
| 99.1 | Financial Appendix |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | ||
| Date: October 29, 2026 | By: | /s/ Norimasa Takeda |
|---|---|---|
| Norimasa TakedaChief Accounting Officer and Corporate Controller | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.